Direxion Pharma & Medical Bull 3X

The Hill and Definium Therapeutics Host Forum on Psychedelic Therapy Prospects

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Definium Therapeutics Completes First Patient Dosing in DT120 ODT for Major Depressive Disorder Phase 3 Clinical Trial

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

Definium Therapeutics plans five Phase III studies for DT120 ODT targeting GAD and MDD

Definium Therapeutics Inc Reports Q1 EPS of $(0.71)

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Definium Therapeutics released FY2026 Q1 earnings on May 7 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7099 (forecast USD -0.4953)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

Needham Raises Axsome Therapeutics Target Price to $267

FactSet lowers Axsome Therapeutics' 2026 EPS forecast

Axsome Therapeutics Reports Strong Q1 2026 Earnings, Core Product Receives FDA Approval for New Indication

Corcept Therapeutics Reports Q1 2025 Earnings

Axsome Therapeutics Reports Strong Q1 Earnings, Ovelity Receives FDA Approval

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Johnson & Johnson

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

ABBV

ARKG

SBIO

In turbulent markets, investors favor high-dividend stocks. Benzinga highlights three healthcare stocks: AbbVie (3.30% yield), GSK (3.58% yield), and Bristol-Myers Squibb (4.40% yield). Analysts provide ratings and price targets, with AbbVie receiving an Overweight rating and a price target increase. GSK's stock was downgraded by Barclays but upgraded by Jefferies. Bristol-Myers Squibb announced a partnership for early-stage programs. Real-time updates are available on Benzinga's platform.

benzinga_article

Abbvie

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Piper Sandler Cos

Barclays

Jefferies Financial

Bank of America

Hengrui Pharma

HENGRUI PHARMA

GlaxoSmithKline plc

GSK plc Sponsored ADR

Bristol-Myers Squibb Company

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

LABU

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Merck

AstraZeneca

ProShares Ultra Health Care ETF

Direxion S&P Biotech Bull 3X

AstraZeneca PLC

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

IBBQ

Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

State Street

Legal & General Group Plc

State Street® US Equity Premium Inc ETF

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

HIMS

HIMY

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Invesco S&P 500 Equal Weight Health Care ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

SPDR S&P Health Equip

iShares US Healthcare Providers

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

Allworth Financial LP increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 106.4% in Q4, owning 217,248 shares valued at $11.7 million. Other institutional investors also raised their holdings. Analysts have set target prices ranging from $40 to $68, with a consensus rating of 'Hold' and an average target price of $61.31. The stock opened at $56.76, with a market cap of $115.91 billion.

Morgan Stanley

HSBC Holdings Plc

HSBC

HSBC HOLDINGS

ROYAL BANK OF CANADA

GRAIL

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

Bristol Myers Squibb Company $BMY Shares Acquired by Allworth Financial LP

Tempus AI Inc. and Bristol Myers Squibb Co. have announced a collaboration to enhance clinical trial design using AI and real-world data across oncology and Alzheimer's programs. The initiative aims to improve drug development strategies by analyzing multimodal patient records to identify suitable patient populations and validate control groups. This partnership builds on existing efforts to address care gaps in advanced lung cancer. Tempus AI shares fell 0.96% to $45.88, while Bristol Myers Squibb shares rose 0.34% to $56.58.

Tempus AI

S&P 500

Taiwan Semiconductor

Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

600276

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

01276

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

Direxion Pharma & Medical Bull 3X(PILL.US)